FDA oversight questioned

被引：0

|

作者：

Mitka, Mike

机构：

来源：

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 2007年 / 298卷 / 22期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

收藏

页码：2611 / 2611

页数：1

相关论文

共 50 条

[21] A Brief History of FDA Compounding Oversight
Shulman, Stanford T.
PEDIATRIC ANNALS, 2013, 42 (01):
[22] FDA OVERSIGHT OF CLINICAL TRIALS The US FDA and regulatory free fall
Wilson, Mark
BMJ-BRITISH MEDICAL JOURNAL, 2023, 380
[23] Edible Cannabis Products: It Is Time for FDA Oversight
Benjamin, David M.
Fossler, Michael J.
JOURNAL OF CLINICAL PHARMACOLOGY, 2016, 56 (09): : 1045 - 1047
[24] Texas legitimizes path around FDA oversight
Laura DeFrancesco
Nature Biotechnology, 2012, 30 : 379 - 379
[25] FDA enhances oversight of postmarket drug safety
Reactions Weekly, 2012, 1400 (1) : 2 - 2
[26] FDA bioproduct oversight shifts to drug division
Wong, JF
GENETIC ENGINEERING NEWS, 2002, 22 (17): : 55 - +
[27] FDA's Framework for Regulatory Oversight of LDTs
Pathak, Bhagyashri
Terry, Sharon F.
GENETIC TESTING AND MOLECULAR BIOMARKERS, 2014, 18 (12) : 785 - 786
[28] Outsourcing challenges FDA to strengthen oversight abroad
Torres, Christian
NATURE MEDICINE, 2010, 16 (02) : 139 - 139
[29] Texas legitimizes path around FDA oversight
DeFrancesco, Laura
NATURE BIOTECHNOLOGY, 2012, 30 (05) : 379 - 379
[30] Pandemic Alters FDA Inspections and Quality Oversight
Wechsler, Jill
BIOPHARM INTERNATIONAL, 2021, 34 (11) : 8 - 9

← 1 2 3 4 5 →